IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Milano.
AIR nasce in UNIMI nel 2006 con lo scopo di raccogliere, documentare e conservare le informazioni sulla produzione scientifica dell'Università degli Studi di Milano e costituisce di fatto l'Anagrafe della ricerca dell'Ateneo.
EnglishBackground: Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved. Aims: To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver. Methods: We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years. Results: The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune-related adverse events involving the liver are a growing concern related to their widespread use. Conclusions: Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.
Review article : immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects / A. Lombardi, M.U. Mondelli. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 50:8(2019), pp. 872-884. [10.1111/apt.15449]
| Titolo: | Review article : immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects | |
| Autori: | ||
| Parole Chiave: | Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Hepatitis B, Chronic; Humans; Immunologic Factors; Immunotherapy; Liver Neoplasms; Treatment Outcome | |
| Settore Scientifico Disciplinare: | Settore MED/12 - Gastroenterologia | |
| Data di pubblicazione: | 2019 | |
| Rivista: | ||
| Tipologia: | Article (author) | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/apt.15449 | |
| Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
Pubblicazioni consigliate
Copyright © 2021